Newly released Continuing Medical Education Training Program focuses on adult brain tumors
This web-based educational activity, Latest Advances in the Diagnosis and Treatment of Malignant Gliomas, produced by our subsidiary, The Kelly Heinz-Grundner Brain Tumor Foundation, in partnership with Abramson Cancer Center of the University of Pennsylvania, has been designed for radiologists, neuro-surgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare professionals interested in the treatment of gliomas. When patients present with neurological or cognitive deficits indicating a possible brain tumor, crucial decisions must be made to produce an accurate diagnosis, effective treatment plan, and hopeful prognosis. This multidisciplinary educational activity outlines the latest innovative approaches to treat patients with newly diagnosed tumors. The course is CME-certified by the University of Pennsylvania School of Medicine. This activity has been approved for AMA PRA Category 1 Credits™. A non-credit version of the program is also available for members of the general public. The course is available 24 hours a day, seven days a week.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Pennsylvania School of Medicine and The Kelly Heinz-Grundner Brain Tumor Foundation, Inc., a subsidiary of the National Brain Tumor Society. The University of Pennsylvania School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Pennsylvania School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is supported in part by educational grants from the Delaware Department of Health and Social Services, Division of Public Health, through The Kelly Heinz-Grundner Brain Tumor Foundation, Inc., a subsidiary of the National Brain Tumor Society, and Varian Medical Systems Foundation, an advised fund of Silicon Valley Community Foundation. It is also supported in part by an educational grant from Genentech.